Inventor · disambiguated record
Kimberly Fultz
Also filed as: FULTZ KIMBERLY · FULTZ KIMBERLY E · FULTZ KIMBERLY ELIZABETH
8 granted patents·6 pending applications·159 citations·filing 2009–2024
88Inventor score
Files withSIGNAL PHARM LLC6ADARX PHARMACEUTICALS INC4PERRIN-NINKOVIC SOPHIE3ADARX PHARMACEUTICAL INC1
Top patents by PatentIndex Score
14 records- 0196US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0296US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0393US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0490US10004735B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2017·Granted Jun 26, 2018·4 cites·16 claims
- 0590US9737535B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2015·Granted Aug 22, 2017·5 cites·16 claims
- 0690US9155736B2Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activitySIGNAL PHARM LLC·Filed 2013·Granted Oct 13, 2015·16 cites·6 claims
- 0780US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 0870US9557338B2Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activitySIGNAL PHARM LLC·Filed 2015·Granted Jan 31, 2017·1 cites·4 claims
- 0962US2025073256A1Prekallikrein-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1061US12042509B2Prekallikrein-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2022·Granted Jul 23, 2024·0 cites·36 claims
- 1161US2024041913A1Angiotensinogen-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1254US2024401045A1Angiotensinogen-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1348US2023272391A1Adar dependent editing compositions and methods of use thereofADARX PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 1443US2014113904A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kimberly Fultz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →